Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATA3219 in Systemic Lupus Erythematosus
NCT06429800Phase 1Withdrawn
- Sponsor
- Atara Biotherapeutics
- Start
- Apr 2025
- Primary completion
- Apr 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of ATA3219 in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (8 cohorts), sponsored by Atara Biotherapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 90 days, Dose-Limiting Toxicities at 28 days and 2 more. Planned start Apr 2025; status: withdrawn.
02
Drugs
ATA3219
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06429800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429800.